Analysis of the dinucleotide repeat polymorphism in the epidermal growth factor receptor (EGFR) gene in head and neck cancer patients.

BACKGROUND Epidermal growth factor receptor (EGFR) overexpression is associated with poor prognosis in head and neck cancer. The first intron of EGFR gene is polymorphic (9-23 CA repeats) and transcription declines when the number of repeats increases. PATIENTS AND METHODS EGFR polymorphism (fluorescent genotyping) and expression (ligand-binding assay) were analyzed in tumors and normal tissues from 112 patients (100 men, 12 women; mean age 60 years). RESULTS The number of CA repeats varied from 15 to 22. Allelic distribution was trimodal (predominance of 16, 20 and 18 CA repeats). EGFR concentrations were significantly higher (P=0.02) in homozygous tumors as compared with heterozygous. Considering homozygous tumors, or classifying genotypes as short/long/intermediary (two alleles <17 versus two alleles > or =17 versus others), no relationship was observed between tumoral EGFR genotype and expression. In the 76 tumors exhibiting at least one 16-CA allele, the length of the remaining allele was inversely correlated to EGFR expression (P=0.047). Tumoral EGFR expression, performance status (WHO criteria) and node involvement were independent predictors of specific survival (P <0.01). Tumoral or normal tissue EGFR genotype did not influence survival. CONCLUSIONS Intron 1 EGFR polymorphism may be implicated in the regulation of EGFR expression in head and neck tumors.

[1]  C. Iacobuzio-Donahue,et al.  Genotypic bases of EGFR inhibitors pharmacological actions , 2004 .

[2]  J. Baselga,et al.  Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): Results of a phase II study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  N. Magné,et al.  Pharmacological background of EGFR targeting. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[5]  J. Isola,et al.  Allelic length of a CA dinucleotide repeat in the egfr gene correlates with the frequency of amplifications of this sequence—first results of an inter‐ethnic breast cancer study , 2004, The Journal of pathology.

[6]  A. Lassman.  Molecular biology of gliomas , 2004, Current neurology and neuroscience reports.

[7]  J. Koropatnick,et al.  Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  C. Liedtke,et al.  Gene dosage PCR and fluorescence in situ hybridization reveal low frequency of egfr amplifications despite protein overexpression in invasive breast carcinoma , 2004, Laboratory Investigation.

[9]  L. Ellis,et al.  Targeting the epidermal growth factor receptor: an important incremental step in the battle against colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  W. Wu,et al.  Nicotine Promoted Colon Cancer Growth via Epidermal Growth Factor Receptor, c-Src, and 5-Lipoxygenase-Mediated Signal Pathway , 2004, Journal of Pharmacology and Experimental Therapeutics.

[11]  M. Hidalgo,et al.  Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Crawford,et al.  Activation of tyrosine kinases in cancer. , 2003, The oncologist.

[13]  R. Perez-soler.  Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? , 2003, Oncology.

[14]  E. Cook,et al.  Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  J. Grandis,et al.  The role of epidermal growth factor receptor in head and neck squamous cell carcinoma , 2003, Current oncology reports.

[16]  J. Mendelsohn.  Targeting the epidermal growth factor receptor for cancer therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  G Milano,et al.  Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 (‘Iressa’) , 2002, British Journal of Cancer.

[18]  J. Hacia,et al.  Molecular pathology of head and neck cancer. , 2002, Histology and histopathology.

[19]  H. Nagatsuka,et al.  Quantitation of epidermal growth factor receptor gene amplification by competitive polymerase chain reaction in pre-malignant and malignant oral epithelial lesions. , 2001, Oral oncology.

[20]  G. Tortora,et al.  A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  C. Arteaga.  The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Baselga,et al.  Targeting the epidermal growth factor receptor: a clinical reality. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Y. Yarden.  The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. , 2001, European journal of cancer.

[24]  B. Brandt,et al.  Modulation of EGFR gene transcription by secondary structures, a polymorphic repetitive sequence and mutations--a link between genetics and epigenetics. , 2000, Histology and histopathology.

[25]  R. Simon,et al.  Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression. , 2000, Cancer research.

[26]  K. Zänker,et al.  Modulation of Epidermal Growth Factor Receptor Gene Transcription by a Polymorphic Dinucleotide Repeat in Intron 1* , 1999, The Journal of Biological Chemistry.

[27]  G. Poissonnet,et al.  A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil , 1999, British Journal of Cancer.

[28]  Jun Wang,et al.  Prepubertal genistein treatment modulates TGF-α, EGF and EGF-receptor mRNAs and proteins in the rat mammary gland , 1998, Molecular and Cellular Endocrinology.

[29]  M. Roth,et al.  Histopathologic and molecular alterations in bronchial epithelium in habitual smokers of marijuana, cocaine, and/or tobacco. , 1998, Journal of the National Cancer Institute.

[30]  J. Rodrigo,et al.  Amplification of ERBB oncogenes in squamous cell carcinomas of the head and neck , 1996 .

[31]  J. Grandis,et al.  Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. , 1993, Cancer research.

[32]  P. Bornstein,et al.  Interactions between the promoter and first intron are involved in transcriptional control of alpha 1(I) collagen gene expression , 1988, Molecular and cellular biology.